<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980054</url>
  </required_header>
  <id_info>
    <org_study_id>HR-BLTN-III-EBC</org_study_id>
    <nct_id>NCT03980054</nct_id>
  </id_info>
  <brief_title>A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer</brief_title>
  <official_title>A Phase III Study to Evaluate the Efficacy and Safety of Pyrotinib Versus Placebo in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind multicenter Phase III study for evaluating the efficacy&#xD;
      and safety of pyrotinib in women with early stage high-risk breast cancer after adjuvant&#xD;
      trastuzumab. The main purpose of this study is to investigate whether pyrotinib can further&#xD;
      reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after&#xD;
      adjuvant treatment with trastuzumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 12, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pyrotinib versus Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Invasive Disease-free Survival (iDFS)</measure>
    <time_frame>From randomization until time of event up to 2 years</time_frame>
    <description>Invasive disease-free survival time is defined as the time from date of randomization until the first invasive disease recurrence of the following events: invasive ipsilateral breast tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, distant recurrence and death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>From randomization until time of event up to 2 years</time_frame>
    <description>Disease-free survival time is defined as the time from date of randomization until the first disease recurrence of the following events: invasive ipsilateral breast tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, non-breast primary invasive cancer, ductal carcinoma in situ(DCIS),or distant recurrence and death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Overall survival is defined as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance Disease-free Survival (DDFS)</measure>
    <time_frame>distant recurrence From randomization until time of event up to 2 years</time_frame>
    <description>Distance Disease-free Survival is defined as the time from date of randomization until the first distant recurrence and death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1192</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm Pyrotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: Pyrotinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: Drug: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>pyrotinib 400 mg, orally once daily for one year</description>
    <arm_group_label>Arm Pyrotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo 400mg, orally once daily for one year</description>
    <arm_group_label>Arm Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients, 18 years ≤ age ≤ 75 years；&#xD;
&#xD;
          -  Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1&#xD;
&#xD;
          -  Histologically confirmed invasive HER2 positive breast cancer.&#xD;
&#xD;
          -  Known hormone receptor status.&#xD;
&#xD;
          -  Cardiovascular: Baseline left ventricular ejection fraction (LVEF)≥55% measured by&#xD;
             Echocardiogram.&#xD;
&#xD;
          -  Been treated for early breast cancer with standard of care duration of trastuzumab.&#xD;
&#xD;
          -  If been not treated neoadjuvantly, lymph node metastases need to be confirmed by&#xD;
             postoperative pathology; if been treated neoadjuvantly , have not reached totally&#xD;
             pathologic complete response.&#xD;
&#xD;
          -  Signed informed consent form (ICF) .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive clinical and radiologic assessments for local or regional recurrence of&#xD;
             disease at the time of study entry.&#xD;
&#xD;
          -  History of heart disease.&#xD;
&#xD;
          -  Bilateral breast cancer.&#xD;
&#xD;
          -  Corrected QT (QTc) interval ≥0.47 seconds.&#xD;
&#xD;
          -  History of gastrointestinal disease with diarrhea as the major symptom.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhimin Shao</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

